Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Finek, J. [1 ,2 ]
Poprach, A. [3 ,4 ]
Melichar, B. [5 ,6 ]
Kopecky, J. [7 ,8 ]
Zemanova, M. [7 ,8 ]
Buchler, T. [7 ,9 ]
Kopeckova, K. [10 ,11 ]
Mlcoch, T. [12 ]
Dolezal, T. [4 ,13 ]
Fiala, O. [1 ,2 ]
机构：
[1] Charles Univ Prague, Teaching Hosp Pilsen, Dept Radiotherapy & Oncol, Plzen, Czech Republic
[2] Charles Univ Prague, Fac Med Pilsen, Plzen, Czech Republic
[3] Masaryk Univ, Masaryk Mem Canc Inst, Clin Comprehens Canc Care, Brno, Czech Republic
[4] Masaryk Univ, Fac Med, Brno, Czech Republic
[5] Palacky Univ, Fac Med & Dent, Olomouc, Czech Republic
[6] Univ Hosp, Olomouc, Czech Republic
[7] Charles Univ Prague, Fac Med 1, Oncol, Prague, Czech Republic
[8] Gen Univ Hosp, Prague, Czech Republic
[9] Thomayer Hosp, Prague, Czech Republic
[10] Univ Hosp Motol, Dept Oncol, Prague, Czech Republic
[11] Charles Univ Prague, Fac Med 2, Prague, Czech Republic
[12] Inst Hlth Econ & Technol Assessment, HTA Dept, Prague, Czech Republic
[13] Masaryk Univ, Inst Hlth Econ & Technol Assessment, Dept Pharmacol, Prague, Czech Republic
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
957P
引用
收藏
页码：387 / 387
页数：1
相关论文
共 50 条
  • [1] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bex, Axel
    Blank, Christian
    Chowdhury, Simon
    Nichol, David
    Peters, John
    Horenblas, Simon
    O'Brien, Tim
    Sarwar, Naveed
    Haanen, John
    Powles, Thomas
    JOURNAL OF UROLOGY, 2011, 185 (04): : E709 - E710
  • [3] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    ONCOLOGIST, 2023, 28 : S5 - +
  • [4] Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
    Jakub Kucharz
    Agnieszka Giza
    Paulina Dumnicka
    Marek Kuzniewski
    Beata Kusnierz-Cabala
    Pawel Bryniarski
    Roma Herman
    Aneta Lidia Zygulska
    Krzysztof Krzemieniecki
    Medical Oncology, 2016, 33
  • [5] Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
    Kucharz, Jakub
    Giza, Agnieszka
    Dumnicka, Paulina
    Kuzniewski, Marek
    Kusnierz-Cabala, Beata
    Bryniarski, Pawel
    Herman, Roma
    Zygulska, Aneta Lidia
    Krzemieniecki, Krzysztof
    MEDICAL ONCOLOGY, 2016, 33 (10)
  • [6] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [8] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    CANCER, 2014, 120 (01) : 52 - 60
  • [9] Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer
    Uhlig, Annemarie
    Uhlig, Johannes
    Trojan, Lutz
    Woike, Michael
    Leitsmann, Marianne
    Strauss, Arne
    FUTURE ONCOLOGY, 2021, 17 (01) : 45 - 56
  • [10] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
    Verzoni, Elena
    Iacovelli, Roberto
    Rizzo, Mimma
    Felici, Alessandra
    Cascinu, Stefano
    Di Lorenzo, Giuseppe
    Cerbone, Linda
    Ortega, Cinzia
    Masini, Cristina
    Giganti, Maria Olga
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Tassi, Renato
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345